StockWatch
·

Anthem Biosciences Ltd Q2 FY27 Results

ANTHEMQ2 FY27 Results
Filing
Result:Very Good· Market: Up#Margin expansion#Cost led#Record quarter

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue594.0342.0%8.0%
Total Income652.9347.4%9.1%
Expenditure356.5619.4%3.3%
PBT296.37105.0%29.1%
Net Profit211.4676.3%21.9%
OPM45.70%9.70pp6.08pp
NPM32.39%5.32pp3.40pp
EPS3.7576.1%21.4%
View full financials

CRDMO-led PAT growth of 21.9% YoY with OPM up 608bps on cost discipline (not one-offs) marks a clear standout for pharma/CRDMO despite only moderate revenue growth.

ANTHEM BIOSCIENCES · Q2 FY27 · THE VERDICT

Margin Surge Masks a Growth Miss — Anthem's ₹211 Crore Quarter Requires Scrutiny

Reported profit grew 21.9% YoY on margin expansion, but revenue rose just 8% — a sharp miss versus the prior implied ≥20% guidance. The call reveals a company pivoting on cost, not scale.

06 Nov 2026 · 6 min read
Reported Revenue

₹594 Cr

+8% YoY vs prior ≥20%

Reported PAT

₹211 Cr

+21.9% YoY

Reported EBITDA margin

50.6%

+300 bps QoQ

Adjusted EBITDA margin

~48%

ex ₹59 Cr other income

The tension is stark. Anthem's profit jumped 22%, but the revenue that feeds it grew just 8% — half what prior guidance implied. The delta comes from two places: a 300-basis-point margin expansion driven by China de-risking and in-house manufacturing ramp, and ₹59 crore in other income (likely MTM or fair-value gains) that inflates the bottom line. Strip that out, and underlying EBITDA margin is ~48%, still strong but not the 50.6% headline. The real story: Anthem swapped growth for margin — a defensive posture that signals caution on the biotech order book.

Management's claims vs. what holds up

The call offered four main assertions. Here's where they stand.

Robust Q2 performance with strong growth

Overstated

Revenue ₹594 Cr, +8% YoY (Q1 weak, Q2 recovery +42% QoQ). PAT ₹211 Cr, +21.9% YoY.

Margin expansion sustained, operating leverage intact

Supported

EBITDA 50.6%, PAT 32.04% in Q2. QoQ improvement from reduced China reliance (now ~20–21% of procurement) confirmed.

Double-digit growth will be delivered for FY27

Overstated

H1 YoY growth implied ~7–8% (₹1,012 Cr vs prior-year ~943 Cr). Q1 weak, Q2–Q4 catch-up needed. Management now hedges: 'try to deliver double-digit.'

Capex ₹1,200 Cr for Unit 4 Phase 1 remains on track

Supported

FY27 capex ₹700 Cr intact, Unit 4 Phase 1 ₹1,200 Cr over 2 years reaffirmed. Phase 2 equivalent scale post-approval (FY28).

Q2 FY27 PAT bridge, ₹ Cr
-37.6454.12145.88237.64211Reported PAT-11Other income200Adjusted PAT
Other income of ₹59 Cr in Q2 (vs ₹48 Cr in Q2 FY26) inflates headline profit. Underlying operating profit remains strong but margin is closer to 48% EBITDA.

What changed on this call

Growth guidance vagueness: Prior call implied FY27 growth 'intact' and 'in line with historical performance' (≥20% threshold). Q2 delivery of +8% YoY signals a miss. Management now defers to 'try to deliver double-digit growth' — stripped of specificity, this is a retreat. Gawir Baig (CFO) explicitly refused to quantify: 'We refrain from giving any guidance on what the full year number is.'

Margin expansion confirmed via China de-risking: China procurement fell from historic highs to ~20–21% of procurement. In-house manufacturing ramp and product mix (higher-margin molecules) drove the 300-bps EBITDA margin improvement. This is durable cost discipline, not a one-off. But it masks lumpy order flow: Q1 was weak, Q2 recovery required, Q2–Q4 catch-up pending.

Capex roadmap reaffirmed, but new tech unquantified: FY27 capex ₹700 Cr and Unit 4 Phase 1 (₹1,200 Cr, commissioning starts Mar 2028) remain intact. New tech (peptides, ADCs, oligonucleotides) still early — in development since 2014 with no FY31 revenue contribution quantified. Ajay Bhardwaj (MD/CEO): 'FY31, we have not even done this calculation.'

Pipeline milestone: One molecule moved from late-stage to commercial in Q2 (chronic-care indication). Five recent commercializations carry ~$10 billion aggregate market potential. But 9 late-stage molecules remain on an 18–24 month timeline with trial outcomes outside Anthem's control.

The honest read

Anthem is executing on cost and capex, but growth has stalled. The margin expansion masks a company managing order lumpiness — Q1 weak, Q2 recovery, Q2–Q4 catch-up required. The prior call's implicit ≥20% FY27 growth target now reads as over-optimistic; management's current 'try to deliver double-digit' is a hedge that signals execution uncertainty. What changed: cost discipline is real, but growth guidance credibility is worn.

For holders, the debate hinges on whether biotech funding stabilizes and late-stage molecules commercialize on the expected 18–24 month timeline. For fresh money, the risk/reward tilts toward caution: the stock has rallied 57.7% off its 52-week low but now sits 6.5% below its all-time high, suggesting limited upside cushion if FY27 growth disappoints again.

Risks, ranked by how much they should concern a holder

Revenue growth shortfall vs. guidance

High

Q2 +8% YoY vs. prior ≥20% implied. H1 ~7–8% makes FY27 double-digit target challenging. If Q3–Q4 growth disappoints, stock faces downside risk.

Customer concentration (top 5 = 50%, top 10 = 80%)

High

Single customer loss or wallet-share reduction could materially impact revenue. Biotech customer base also exposed to M&A cycles and funding volatility.

Late-stage pipeline timing uncertainty (9 molecules, 18–24 months)

High

Commercialization outcomes depend on trial results (not Anthem's control). Delay or failure impacts near-term and mid-term growth trajectory.

Biotech funding volatility and geopolitical headwinds

Medium

RFP/RFQ inflow improved but AI crowding and geopolitical uncertainty dampen order book visibility. Order lumpiness (Q1 weak, Q2 recovery) signals customer hesitation.

Earnings quality / other income dependency

Medium

₹59 Cr other income (vs ₹48 Cr prior year) inflates headline profit. Underlying EBITDA margin ~48%, not 50.6%. If other income normalizes, profit growth resets lower.

New tech commercialization unquantified (FY31 target missing)

Medium

Unit 4 capex (₹1,200 Cr) betting on peptides, ADCs, oligonucleotides still in early stages (since 2014). No revenue target for FY31 — capex ROI visibility absent. Typical 6–7 years to Phase 3.

How the street is positioned

Price action and valuation context: Anthem trades at ₹913.55, above its SMA20 (₹843.26), SMA50 (₹881.51), and SMA200 (₹771.35). RSI 66.6 signals neutral momentum (not overbought). The stock sits 6.5% below its all-time high of ₹977.45 and 57.7% above its 52-week low of ₹579.15 — a strong recovery from the trough, but diminishing upside to ATH. Volume remains normal; no panic or euphoria on the tape.

Institutional flows — accumulation signal: FII holdings rose from 1.28% (Q4 FY26) to 2.58% (Q1 FY27), a +1.3pp increase. DII holdings rose from 11.55% to 13.48%, a +1.93pp increase. Promoter holdings fell from 74.68% to 71.42%, a -3.26pp step. The net: institutions are adding, promoters are trimming slightly (likely to fund capex or optimize holding). This is a mild bullish signal — FII/DII accumulation often precedes a sustained move — but the scale is modest, not aggressive.

Bulk/block deals (last 6 months): All major blocks were buys, at ₹744.80 — a price 22.6% below the current ₹913.55. UTI MF, SBI MF, WhiteOak Capital MF, and others accumulated on weakness. No promoter or insider sales near the highs — a clean record. The bulk buying by MFs on dips suggests confidence in the long-term story, but occurred when the stock was materially cheaper. No insider signal of near-term strength.

The tension: The market has repriced Anthem 57.7% higher from the 52-week low, betting on capex and margin expansion. But it has not yet repriced for the revenue growth miss. If Q3–Q4 fail to accelerate growth toward double-digit, the stock faces a test: institutional holders (who just added) will face a credibility gap between the capex roadmap and the delivery, and the 6.5% headroom to ATH may vanish.

What to watch next
  • 1 · Q3 FY27 earnings: growth inflection or disappointment

    Does management deliver mid-double-digit growth in Q3, or does the order lumpiness persist? H1 growth ~7–8% means Q3–Q4 average needs to hit ~15%+ to reach FY27 double-digit. This is the crux test for bulls.

  • 2 · Late-stage pipeline updates: commercialization rate

    How many of the 9 late-stage molecules move toward commercial status? Management expects 'at least a few' in FY27–FY28. Concrete progress validates the capex thesis; silence signals pipeline risk.

  • 3 · Unit 4 commissioning timeline and Phase 1 ramp

    Commissioning starts Mar 2028. Capacity ramp a multi-quarter process. Will new capacity fill with biotech/big pharma order flow, or sit idle amid funding volatility? This determines whether capex (₹1,200 Cr over 2 years) generates ROI.

  • 4 · Customer concentration relief: do new tech/big pharma partnerships dilute top-5 risk?

    Management claims 8–9 big pharma direct relationships emerging. Block/lateral contract wins with secondary suppliers would ease the top-5 = 50% concentration. Announcements on new wins matter.

  • 5 · Specialty Ingredients (SI) 20% target: execution or promise?

    SI flat in Q2 due to weak CRDMO. Management wants SI at ≥20% of sales (currently 15%). If SI stalls while CDMO growth disappoints, this target remains unmet.

Anthem delivered steady execution on cost and capex, but not on growth. The 8% revenue growth is a step backward from prior guidance, and management's pivot to a vague 'try to deliver double-digit' for FY27 signals execution uncertainty. The margin expansion is durable and credible — a win. But it masks an order book that remains lumpy and a biotech customer base still managing funding volatility. The capex roadmap (Unit 4 ₹1,200 Cr, commissioning Mar 2028) is the multi-year bull case; the near-term debate is whether revenue can recover to double-digit without new capacity coming online.

The number to track from here: FY27 full-year revenue growth. If Q3–Q4 deliver sub-double-digit growth, the guidance miss becomes permanent, and the stock's 57.7% rally from the 52-week low faces headwind. Institutional holders just added on dips; they will expect management to deliver on the implicit ≥20% thesis. A third consecutive miss accelerates de-rating risk.

Informational and educational content only. Not investment advice.